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Abstract
The expression of insulin receptor (IR) in β-cells suggests an autocrine role for insulin
signalling in β-cell function and regulation. Studies have demonstrated that β-cell Ir
knockout (βIrKO) mice develop age-dependent glucose intolerance. We investigated the
temporal role of β-cell IR signaling in pre- and postnatal islet development and function,
and under high-fat diet stress, using a tamoxifen-inducible Cre-recombinase Ir knockout
mouse model.
Prenatal βIrKO mice exhibited increased mean islet area, β-cell area, and islet area
percentage. Additionally, there was upregulation of insulin-like growth factor-2 levels,
increased Akt activity, and increased proliferation in islets. Postnatally-induced βIrKO
mice did not exhibit impaired glucose tolerance at 4, 8, and 20 weeks post-tamoxifen.
Similarly, no differences were observed between groups on high-fat diet. Results suggest
that while loss of fetal β-cell IR causes an islet growth response through alternate
pathways, postnatal β-cell IR may not play a pivotal role for adult β-cell function.
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Chapter 1 - Introduction
1.1

Significance of study2
Pancreatic development is a complex process that requires temporal regulation of

both transcription factor expression and intricate signalling pathways to generate
physiologically functional mature adult islets. The β-cell insulin receptor (IR) has been
previously shown to influence islet survival and function through autocrine insulin
signalling in postnatal life. However, the temporal importance of β-cell insulin receptor
signalling on the islet morphology, expression of transcription factors, and metabolic
proteins necessary for β-cell maturation, proliferation, and survival has yet to be
sufficiently investigated. In addition, the knowledge of the physiological function of
insulin signalling during fetal β-cell embryogenesis is crucial for understanding abnormal
islet development and maturation in utero. This thesis demonstrates that the intracellular
mechanisms of insulin receptor-mediated signalling that regulate β-cell development,
survival, and function vary during different stages of life and during diabetes progression.
These results will contribute to improving long-term success of current cell-based
therapies for diabetes.

1.2

The pancreas and islet of Langerhans3
The pancreas is an organ that contributes to digestion and glucose regulation, and

consists of both exocrine and endocrine compartments. In the exocrine tissue (~98% of
the pancreas), acinar cells secrete digestive enzymes through specialized duct cells into
the duodenum. The endocrine compartment (~2% of the pancreas) is composed of
functional clusters of cells known as the islets of Langerhans, which contain multiple cell
types that secrete distinct hormones. Murine islets are comprised of predominantly
insulin-secreting β-cells (~80%) that form the central core and are surrounded by
glucagon-secreting α-cells (~10%), while the remaining endocrine cell types are
pancreatic polypeptide secreting γ-cells, somatostatin-secreting δ-cells, and ghrelinsecreting ε-cells. Out of these endocrine cells, α- and β-cells have important opposing
1

physiological effects on blood glucose homeostasis. In response to sensing
hypoglycemia, α-cells secrete glucagon that then promotes the liver to facilitate
glycogenolysis and gluconeogenesis, leading to an increase in blood glucose
concentrations. In contrast, high blood glucose levels stimulate β-cells to produce and
release insulin, which stimulates glucose uptake from the bloodstream into skeletal
muscle, liver, and adipose tissues for energy storage. Therefore, proper development of
the pancreas, specifically the β-cells, is critical in meeting the dynamic metabolic demand
under both physiological and pathological conditions (Montanya et al. 2000).

1.3

Pancreas development & β-cell formation4
The murine pancreas undergoes three different transition stages of pancreatic

development, where the pancreas starts to form from the endoderm at embryonic day 8.5
(e8.5, where e0.5 is defined as the day of observing vaginal plug in the pregnant female).
During the primary transition (e9.5-e12.5), regions of endodermal gut tube express the
required transcription factors needed for pancreatic development, pancreatic duodenal
homeobox 1 (Pdx-1) and pancreas transcription factor 1a (Ptf1a), and form the ventral
and dorsal buds of the pancreas (Offield et al. 1996, Kawaguchi et al. 2002, Gittes 2008).
During this time, the first wave of endocrine differentiation begins and is critically
dependent on the expression of the transcription factor neurogenin 3 (Ngn3), which is
activated after Notch activity is downregulated, and the subsequent activation of NK
homeobox 6.1 (Nkx6.1). However, the insulin-positive β-cells that emerge early in the
development within endocrine clusters do not contribute to the postnatal mature islets
(Pan et al. 2011, Gunasekaran et al. 2012). Throughout the secondary transition (e12.5e18), the primitive ventral and dorsal pancreatic buds rotate and fuse to form a single
organ, and the cellular architecture changes dramatically in the pancreas. The pancreatic
progenitor cells adopt either 'tip' or 'trunk' identity. The cells in the 'tip' region are fated to
become acinar cells while the 'trunk' region can differentiate into either ducts or
endocrine cells. There is rapid differentiation and branching of acinar and duct cells to
form a complex network. Similarly, there is extensive neogenesis and expansion of
endocrine cells, especially the β-cells, accompanied by the expressions of their essential
2

transcription factors. These expanding islet cells form from or adjacent to pancreatic
ducts, suggesting that precursor cells migrate out of the ductal region to form islet
clusters (Nielsen et al. 1999, Al-Hasani et al. 2013). Unlike primitive endocrine cells
from primary transition, β-cells from secondary transition form mature, functional islets
and serve as the primary source for β-cell replication during late gestation and in adult
mice (Gunasekaran et al. 2012). Lastly, the third transition spans from e18 to 3 weeks
after birth, where the endocrine cells undergo high levels of neogenesis, replication, and
apoptosis, indicating islet expansion, remodelling, and organization in the developing
endocrine pancreas (Kaung 1994, Scaglia et al. 1997). By the end of the third transition,
β-cell neogenesis is rapidly diminished and replaced by β-cell replication, the primary
mechanism responsible for postnatal β-cell formation (Dor et al. 2004). In order to
maintain glucose homeostasis in adult mice, the β-cell mass dynamically changes through
a balance of β-cell replication and apoptosis (Montanya et al. 2000). However, impaired
prenatal development and maturation of islets may lead to the formation of β-cells that
are inadequate for managing metabolic stress in adult life.

1.4

Islet vascularization5
Although the endocrine compartment only comprises ~2% of the mature pancreas

volume, it receives ~10% of the total pancreatic blood flow from the celiac and superior
mesenteric arteries. The islets are highly vascularized, with a dense network of capillaries
that are more fenestrated than the exocrine tissue (Jansson et al. 1983, Henderson et al.
1985, Jansson et al. 2002). This allows for the rapid and efficient exchange of nutrients
and hormones between endocrine cells and the bloodstream. Pancreatic β-cells express
high levels of vascular endothelial growth factor-a (Vegf-a), which stimulates the
recruitment of endothelial cells, promotes the formation of blood vessels during
embryonic pancreas development, and maintains islet vasculature and integrity in
postnatal life (Christofori et al. 1995, Brissova et al. 2006, Reinert et al. 2013).
Furthermore, vascular growth is closely associated with β-cell proliferation (Johansson et
al. 2006) as seen in mice with short-term (~2 weeks) β-cell-specific Vegf-a
overexpression that resulted in islet hypervascularization simultaneous with increased β3

cell proliferation (De Leu et al. 2014). In contrast, long-term (~2 month) overexpression
of Vegf-a in β-cells resulted in disorganized islets with hypervascularization, increased
inflammation, impaired insulin secretion, and decreased β-cell mass with age (Agudo et
al. 2012). These studies suggest that Vegf-a signalling plays an important role in islet
vasculature, β-cell survival, and function in a time-dependent manner.

1.5

Overview of diabetes mellitus6
Glucose homeostasis relies on the fine balance between production by the liver

and utilization by insulin-dependent tissues such as fat and muscle, as well as insulinindependent tissues. Diabetes mellitus is a chronic metabolic disease characterized by a
disruption in glucose homeostasis that can arise due to multiple dysfunctions in the
insulin production and secretion pathway. The resulting hyperglycemia leads to a high
insulin secretory demand, which further exacerbates β-cell function and accelerates β-cell
death. While type 1 diabetes mellitus is characterized by a near absolute deficiency of βcells, the onset of type 2 diabetes mellitus is due to insufficient insulin production, islet
hypervascularization, and progressive β-cell mass reduction. In both cases, β-cell
dysfunction and failure are perceived as the main cause.
Type 1 diabetics (~10% of the total diabetic population) suffer from persistent
autoimmune destruction of the β-cells, and the pathological indicators typically begin to
develop in children and young adults. Due to a loss of up to ~90% of β-cells, patients rely
on perpetual exogenous injections of insulin to regulate their blood glucose levels.
Alternatively, the Edmonton protocol is a standard cell-based therapy that involves
isolation of islets from several cadaveric donors and transplantation into the hepatic
portal vein of immunosuppressed patients, restoring endogenous insulin secretion and
allowing these patients to become independent from exogenous insulin for as long as 5
years (Shapiro 2012). However, islet transplantation is heavily limited by the availability
of cadaveric donors and the therapeutic effectiveness of the current transplantation
protocol.

4

Type 2 diabetes (~90% of the total diabetic population) is characterized by several
pathological defects and typically manifests itself later in adult life. Genetic composition
and environmental factors, especially obesity, have been closely linked to type 2 diabetes
progression. Typically, insulin resistance in insulin-responsive peripheral tissue occurs,
reducing the clearance of glucose from circulation and leading to multiple health
problems that develop from hyperglycemia. The β-cell mass initially expands to
compensate for this insulin resistance but the compensatory mechanism eventually fails,
resulting in decreased β-cell mass and relative deterioration of insulin production and
secretion (Kahn 1994). Furthermore, the chronic islet hypervascularization seen in type 2
diabetics can result in islet fibrosis, inflammation, and ultimately contributes to β-cell
death (Agudo et al. 2012). Type 2 diabetes can be managed by lifestyle improvements,
insulin sensitizers, and if necessary, exogenous insulin. Although symptoms are wellcharacterized, the causes for type 2 diabetes is multifactorial and complex, and some
form of insulin resistance may involve the alteration in the insulin receptor itself,
including decreased receptor levels and activation in the periphery tissues as well as in βcells (Taylor et al. 1990, Pessin et al. 2000, Folli et al. 2011).

1.6

Insulin receptors7
The insulin receptor is a receptor tyrosine kinase that contains two extracellular

regulatory α-subunits and two transmembrane catalytic β-subunits that are linked by
disulfide bonds (Kahn 1993, Lee et al. 1994). IR exists as two isoforms, IR-A and IR-B,
by alternative splicing of the exon 11 in the α-subunit. These isoforms show tissuespecific expression - IR-A (exon 11-) is primarily expressed in fetal cells, with lower
expression in metabolically active adult tissues, such as muscle, liver, and adipose
(Frasca et al. 1999), whereas IR-B (exon 11+) is mainly expressed in liver and muscle
tissues (Frasca et al. 1999, Nakae et al. 2001). Ligand binding to one of the IR α-subunits
induces a conformational change that promotes β-subunits to bind ATP and
autophosphorylate multiple tyrosine residues, leading to the phosphorylation of the
insulin receptor substrate (IRS) proteins and activation of downstream signalling
pathways. Consequently, any loss of tyrosine kinase activity is accompanied by a loss in
5

the ability of the receptor to signal (Kahn 1993). Interestingly, IR and insulin-like growth
factor 1 receptor (IGF1R) have a high degree of structural homology and share similar
downstream substrates, and compensatory upregulation of IGF1R in the absence of IR
has been previously reported (Van Schravendijk et al. 1987, Assmann et al. 2009).

1.7

Insulin receptor ligands8
In low concentrations, insulin binds to IR while insulin-like growth factor-1

(IGF1) activates IGF1R; however, due to the homology between IR and IGF1R
structures, insulin and IGF1 are able to bind to both receptors under higher ligand
concentrations. In addition, insulin-like growth factor-2 (IGF2), which activates its
corresponding receptor (IGF2R), has the ability to bind to both receptors with relatively
high affinities (Figure 1.1)(Louvi et al. 1997, Nakae et al. 2001, Assmann et al. 2009). In
rodents, IGF2 levels rapidly diminishes after birth, indicating its importance in prenatal
development but not in postnatal life (Murphy et al. 1987).

6

Figure 1.1. Ligand signalling through the Insulin/IGF1 receptor family
While insulin and IGF1 ligand bind to their own receptors with high affinity (solid arrows), they
are able to signal through the cognate receptor with lower affinity (dashed arrows) under high
concentrations. Alternatively, IGF2 has the ability to bind to both receptors with relatively high
affinities. Insulin and IGF1 receptor share similar downstream signalling pathways that
contribute to cell proliferation, survival, and glucose metabolism.

7

1.8

Insulin production and secretion9
The production of functional insulin involves multiple post-translational cleaving

steps from preproinsulin (the precursor form) to mature insulin and its storage in
secretory granules. The precise control of β-cell insulin secretion is essential to ensure
regulated glucose homeostasis. Normally, an increase in blood glucose concentration
stimulates insulin secretion by allowing the transport of free calcium into β-cells. This
results in a biphasic insulin secretion response. The first phase (~10 min) corresponds to
the exocytosis of prepared insulin-containing granules triggered by the initial Ca2+ influx.
The second phase involves the prolonged slow release of insulin from granules mobilized
from the reserve pool until euglycemia is achieved, as well as replenishment of insulincontaining granules (Rosman et al. 2000).
It is well established that insulin has a positive autocrine feedback on insulin production
through IR activity (Leibiger et al. 1998, Leibiger et al. 2001). Interestingly, IR-A and
IR-B isoforms show functionally different selective insulin signalling in pancreatic βcells. Insulin binding and activation of IR-A promotes insulin gene transcription, while
the activation of IR-B leads to upregulation of the glucokinase expression in an autocrine
feedback loop (Leibiger et al. 2001, Leibiger et al. 2008). However, the autocrine
regulation of exogenous insulin on insulin secretion in β-cells is controversial. Using 5hydoxytryptamine (5-HT) secretion as a marker of exocytosis in β-cells, amperometric
measurements of exocytosis from single, isolated human and mouse islets demonstrated
increased insulin secretion in response to exogenous insulin treatment (Aspinwall et al.
1999). In contrast, when C-peptide release rates were measured as an indicator of insulin
secretion, exogenous insulin application had no stimulatory effect on endogenous insulin
secretion in isolated perfused rat islets (Zawalich et al. 2002). Transcription factor levels
in β-cells are also responsible for regulating insulin secretion. A reduction in Pdx-1 and
Islet-1 has been linked to impaired glucose-stimulated insulin secretion in β-cells
(Brissova et al. 2002, Gauthier et al. 2009, Ediger et al. 2014), while overexpression of
MafA in neonatal rat islets enhanced insulin synthesis and secretion in response to
glucose stimulation (Aguayo-Mazzucato et al. 2011).
8

1.9

Insulin receptor signalling pathways10
Upon insulin binding to IR, the two major signalling pathways that are activated

are the phosphoinositide 3-kinase (PI3K)/Akt pathway and the Ras/Raf-1/mitogenactivated protein kinase (MAPK) cascade. Insulin receptor signalling plays a mitotic and
metabolic role in a wide variety of tissues. In most metabolically active tissues (muscle,
liver, adipose), the primary function of insulin signalling is to activate PI3K, Akt, and
P70S6K to stimulate protein synthesis, glycogen synthesis, and GLUT-4 translocation to
the cell membrane for facilitating glucose clearance. However, IR signalling in these
tissues contributes to mitogenesis to a lesser degree (Shymko et al. 1997). On the other
hand, in addition to increasing metabolic activities such as insulin synthesis, IR signalling
also plays an essential role in β-cell proliferation and survival (Johnson et al. 2006,
Johnson et al. 2008, Alejandro et al. 2010). Mice lacking IR in β-cells, but not IGF1R,
have increased apoptosis, decreased proliferation, and reduced β-cell mass, demonstrating
the necessity of IR in β-cell survival (Johnson et al. 2008, Wang et al. 2013). In fact,
overexpression of IR in in vitro β-cell cell lines led to enhanced β-cell proliferation and
increased metabolic activities such as insulin production (Xu et al. 1998, Kim et al.
2013).
When examining downstream substrates, studies of in vitro insulinoma cells and
transgenic mouse models overexpressing Akt have suggested that IR signalling promotes
β-cell survival through the Akt pathway (Bernal-Mitzrachi et al. 2001). However, adult
mice lacking β-cell Akt activity did not exhibit increased β-cell apoptosis and retained
normal β-cell mass despite the presence of glucose intolerance due to defective insulin
secretion (Bernal-Mizrachi et al. 2004). This result indicates the involvement of Aktindependent signalling pathways on β-cell survival. Alternatively, the anti-apoptotic and
pro-mitogenic effects of Raf-1/MAPK activities have been strongly implicated in β-cells.
For instance, subjecting mouse islets to exogenous insulin rapidly activated Raf-1
pathway and enhanced β-cell survival, while treatments with Raf-1 inhibitor resulted in
increased β-cell death (Alejandro et al. 2010, Johnson et al. 2008). These studies
emphasize on the essential roles of Akt and Raf-1 signalling pathways on β-cell
9

regulation, but a full understanding of how these pathways control β-cell function is not
yet clear.

1.10 Insulin receptor in different tissues11
IR is expressed in a wide range of tissues and its activation by insulin typically
promotes the uptake of glucose from the blood into skeletal muscle, liver, and adipose
tissues. Global heterozygous deletion of Ir in mice displayed normal phenotype and
physiological glucose homeostasis at 2 months of age, demonstrating that expression of
one Ir allele is sufficient for maintaining euglycemia. Ubiquitous Ir knockout mice,
however, displayed increasing postnatal growth retardation, hyperglycemia,
hyperinsulinemia, and died within one week after birth due to diabetic ketoacidosis (Joshi
et al. 1996, Folli et al. 2011). Similarly, insulin knockout mice also died shortly after
birth due to severe diabetic ketoacidosis and exhibited slight growth retardation (Duvillie
1997). Surprisingly, null Ir mice were indistinguishable at birth from littermates,
suggesting that IR is not required for normal embryonic development (Joshi et al. 1996,
Wicksteed et al. 2010). Igf1, Igf2, and Igf1r were also investigated in a global knockout
manner and were determined to be necessary for proper embryonic development in mice
(DeChiara et al. 1990, Liu et al. 1993).
Since the disruption of insulin signalling in different tissues contributes to type 2 diabetes
pathogenesis, several site-specific Ir knockout models have been examined in mice
(Kitamura et al. 2003). Skeletal muscle is the primary site of insulin-dependent glucose
clearance from blood, and insulin resistance in skeletal muscle is an essential part of the
disease progression in type 2 diabetes (Cline et al. 1999). Notably, skeletal musclespecific Ir knockout mice led to impaired insulin signaling without systemic insulin
resistance, indicating the presence of compensatory mechanisms through the IGF1R and
increased uptake of glucose by other tissues (Shefi-Friedman et al. 2001). Similarly,
adipose-specific Ir knockout produced selective insulin resistance in adipose tissue that
did not affect whole body glucose metabolism (Guerra et al. 2001, Blueher et al. 2002).
The liver plays a vital role in physiological glucose homeostasis as it is subjected to
intricate regulation by insulin, glucagon, and many other hormones. Consequently, liver10

specific Ir knockout mice exhibited hyperinsulinemia, severe insulin resistance, and
glucose intolerance, suggesting the importance of liver IR on glucose homeostasis and
facilitation of insulin clearance (Michael et al. 2000).

1.11 Insulin receptor and β-cells12
Type 2 diabetes disease progression is closely associated with β-cell failure,
particularly the impairment of glucose-stimulated insulin secretion. To elucidate the role
of insulin signalling in mature β-cells, several β-cell-specific Ir knockout studies using
the rat insulin promoter have been conducted in mice. These mice displayed progressive
age-dependent glucose impairment starting as early as 5 weeks of age concomitant with
islet mass reduction, suggesting its importance in maintaining β-cell survival and
function (Kulkarni et al. 1999, Ueki et al. 2006, Okada et al. 2007). Alternatively, mice
with β-cell-specific deletion of the Igf1r exhibited glucose intolerance likely due to the
defective glucose stimulated insulin secretion but their β-cell mass, islet size, and
pancreatic insulin content was unaltered (Xuan et al. 2002, Kulkarni et al. 2002). Taken
together, it seems like β-cell IR, but not IGF1R, is required for postnatal islet survival.
Importantly, both β-cell-specific Ir and Igf1r knockout mice are phenotypically normal at
birth and show no alterations to prenatal pancreatic development (Kulkarni et al. 1999,
Kulkarni et al. 2002, Okada et al. 2007). Therefore, it appears that β-cell IR and IGF1R
play a minor role in pancreatic organogenesis, but are necessary for adaptive islet
function in response to increasing metabolic stress during postnatal life (Smith et al.
1991). Due to the importance of IR in β-cell health and functionality along with the
possibility of compensatory response from IGF1R, IGF1 and IGF2, an in-depth analysis
of β-cell IR functionality during islet development at the molecular morphological level
needs to be implemented.

1.12 High-fat diet, β-cell insulin resistance and dysfunction13
Genetic factors and obesity are often associated with the progression of type 2
diabetes. In various strains of diabetic mouse models, an increase in dietary fat content
has been shown to generate obese mice that develop diabetes. The C57BL/6J mouse (also
11

known as B6) is a widely used type 2 diabetes model as it spontaneously develops
obesity, peripheral insulin resistance, hyperinsulinemia, and hyperglycemia when
restricted to high-fat diet, and often remain physically lean and maintain normal
phenotypes under low-fat chow. Generally, B6 mice develop diabetic symptoms as early
as 1 month after the introduction of high-fat diet (Surwit et al. 1988, Collins et al. 2004,
Okada et al. 2007). At the morphological level, increased β-cell proliferation causes islet
compensatory growth after 14 weeks on high-fat diet. However, these mice exhibited
impaired in vivo glucose tolerance and glucose-stimulated insulin secretion, indicating
that islets are replicating in an attempt to compensate for increased metabolic demand
and insulin resistance, but are insufficient or functionally defective and unable to
maintain normal glucose tolerance (Roat et al. 2014).
Few studies have investigated the role of β-cell insulin signalling in high-fat diet fed prediabetic B6 mice. After 20 weeks of high-fat diet (with 55% fat content), wild-type, βcell-specific Ir knockout, and β-cell-specific Igf1r knockout mice all displayed obesity,
hyperinsulinemia, and hyperglycemia. Out of all the experimental groups, β-cell-specific
Ir knockout mice demonstrated the most severe hyperglycemia and glucose intolerance,
and 30% died after 16 weeks on high-fat diet (Okada et al. 2007). In terms of pancreatic
morphology, these mice failed to develop the islet compensatory growth response
normally seen in wild-type and β-cell-specific Igf1r knockout groups on high-fat diet,
indicating the importance of IR signalling in β-cell growth and survival in response to
metabolic stress during postnatal life. In addition, nuclear Pdx-1 levels were reduced in
these mice, suggesting impaired β-cell growth and function as well as defects in insulin
production (Okada et al. 2007). Consistent with these findings, heterozygous insulin
knockout B6 mice did not develop islet compensatory growth, hyperinsulinemia, or
obesity under high-fat diet (with 58% fat content)(Mehran et al. 2012). Taken together,
these studies highlight the necessity of insulin signalling in modulating islet proliferation
responses in B6 mice on a high-fat diet, and suggest that differing degrees of insulin
signalling affect the progression of diabetes.
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1.13 Rationale, objectives, and hypothesis14
Appropriate pancreatic embryogenesis and remodeling is crucial for the
development of dynamic β-cells that can adapt to changing metabolic demands. Despite
its importance in β-cell function and survival, the molecular mechanisms involved in the
IR signalling pathway, which affects transcription factor expression and proliferation,
during different developmental periods have yet to be studied. We propose investigate the
temporal role of the β-cell IR autocrine/paracrine signalling in fetal and postnatal islet
maturation and function, as well as postnatal mice under high-fat diet conditions, by
utilizing tamoxifen-inducible Cre recombinase under control of the mouse insulin
promoter (MIP) to drive β-cell-specific Ir knockout (Wicksteed et al. 2010, Hayashi et al.
2002, Liu et al. 2010, Tamarina et al. 2014). In contrast to previous studies, we chose to
use MIP instead of RIP because MIP mice appear to lack the ectopic expression seen in
the hypothalamus of RIP mice (Wicksteed et al. 2010, Tamarina et al. 2014). Previous
studies suggested normal pancreatic development at birth despite a lack of β-cell IR from
conception, indicating the presence of network adaptation from other signalling pathways
(Kulkarni et al. 1999, Okada et al. 2007, Ueki et al. 2006). This project investigates the
in-depth characterization of islet morphology during fetal pancreatic development after a
temporal β-cell Ir knockout induced at the secondary transition of pancreas development
(endocrine differentiation and proliferation), and explores the consequential adaptive
signalling from the homologous receptor IGF1R and its ligands, IGF1 and IGF2, that
may contribute to proper pancreatic embryogenesis. In addition, previous β-cell-specific
Ir knockout studies utilized a mouse model with β-cell-specific Ir knockout at
conception, and as a result, these mice lack β-cell IR throughout pancreas embryogenesis.
In contrast, this thesis focuses on the role of β-cell IR in the postnatal life by inducing βcell-specific Ir knockout 4 weeks after birth, allowing undisturbed pancreatic maturation
and remodelling in third transition (Figure 1.2). Lastly, this thesis will utilize the
postnally induced β-cell-specific Ir knockout mice subjected to high-fat diet to
investigate the gene-dose dependent effect of Ir (wild-type, heterozygous, null) on islet
proliferation and function during diabetes progression.
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Objective
To investigate the temporal role of the β-cell IR autocrine/paracrine signalling in fetal
and postnatal islet formation and function, as well as during high-fat diet induced
diabetes pathogenesis.

Hypothesis
1. The β-cell IR is required for normal islet formation and remodelling in prenatal life
2. β-cell autocrine/paracrine insulin signalling is necessary for the maintenance of β-cell
function and survival in postnatal life

Specific Questions
1. Does β-cell-specific Ir knockout affect islet formation during secondary transition?
2. Could the β-cell-specific Ir knockout promote activity of homologous signalling
pathways?
3. Is the level of islet vascularization associated with islet growth during prenatal life?
4. Do postnatally induced β-cell-specific knockout mice exhibit age-dependent glucose
intolerance?
5. Do postnatally induced β-cell-specific knockout mice exhibit glucose intolerance after
high-fat diet stress?

14

Figure 1.2. A schematic of experimental β-cell Ir knockout time points with
reference to important islet development events in rodents.
In rodents, pancreatic development can be separated into 3 transitional phases starting
around embryonic day 9.5 (e9.5). Generally, prenatal β-cell neogenesis persists
throughout prenatal pancreatic formation and maturation, but diminishes after birth and is
replaced by β-cell replication, which becomes the primary mechanism contributing to
postnatal β-cell growth. For our fetal βIrKO studies, tamoxifen was administered (via
intraperitoneal) into pregnant females at e13, and pups were subsequently dissected for
pancreata collection at e19. For our postnatal βIrKO studies, β-cell Ir was knocked out 34 weeks after birth.
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Chapter 2 - Materials and Methods15
2.1

Generation of β-cell-specific Ir knockout mice16
B6.129S4(FVB)-Insrtm1Khn/J mice (IRfl/fl) with loxP sites flanking exon 4 of the Ir

gene were obtained from The Jackson Laboratories (Bar Harbor, MA, USA; stock
number: 006955). Transgenic Tg(Ins1-Cre/ERT)1Lphi (MIPCreERT) mice with tamoxifen
inducible Cre-recombinase expression under the control of the mouse insulin 1 promoter
were obtained from Dr. Louis Philipson’s laboratory (University of Chicago, Chicago, IL
, USA). To verify the mouse insulin 1 promoter-driven Cre recombinase expression in
pancreatic islets, MIPCreERT mice were crossed with a B6.Cg-Gt(ROSA)26Sortm9(CAGtdTomato)Hze

/J reporter strain (stock number: 007909; The Jackson Laboratories). The

transgenic mouse lines MIPCreERT and IRfl/fl were crossed at our research facility
(Victoria Research Laboratories, Victoria Hospital, London, ON, CA) to generate
MIPCreERT+/–;IRfl/+ mice, which were subsequently mated with each other to generate
experimental groups consisting of MIPCreERT+;IR+/+(control), MIPCreERT–;IRfl/fl
(control), MIPCreERT+;IRfl/+(heterozygous), and MIPCreERT+;IRfl/fl (βIrKO) groups
(Figure 2.1A). These genotypes were identified through the polymerase chain reaction
(PCR) procedure described below.
All mice were provided ad libitum access to both food and water. All animal use
protocols were approved by the Animal Use Subcommittee at Western University in
accordance with the Canadian Council of Animal Care.

16

Figure 2.1. Generation of experimental mouse groups
(A) The breeding schematic to generate experimental groups. By intercrossing
MIPCreERT+/–:IRfl/+ mice, we produced experimental animals with the βIrKO genotype
(MIPCreERT+:IRfl/fl, red) alongside control mice (MIPCreERT+:IR+/+ and MIPCreERT–
:IRfl/fl, blue). (B) Genotypes of fetal mice were determined PCR of the Ir and
MIPCreERT genes, followed by gel electrophoresis. Representative images are shown.
17

2.2

Mouse genotyping17
DNA was extracted from fetal (obtained at e19) or adult (obtained at p21) tail

snips using 50 μL of base solution (25 mM NaOH; 0.2 mM EDTA) and placed on a heat
block set at 95 ⁰C for 30 min followed by 1 hour cool down at room temperature.
Subsequently, 50 μL of 40 mM Tris HCI (pH 5.5) was added to each sample for
neutralization and centrifuged at 15616 x g for 1 min. Samples were subjected to PCR to
determine the genotype for each mouse. Primers used for PCR of the IRfl/fl mutation were
oIMR6765 (5’-GATGTGCACCCCATGTCTG-3’) and oIMR6766 (5’CTGAATAGCTGAGACCACAG-3’). Alternatively, primers for MIP (5’CCTGGCGATCCCTGAACATGTCCT-3’) and CreERT (5’TGGACTATAAAGCTGGTGGGCAT-3’) detection were used. PCR products were
separated by an ethidium bromide-containing 2% agarose gel for ~90 min at 80 V. Gels
were imaged under UV light with Gene Genius Bio Imaging System (SynGene;
Frederick, MD, USA) and GeneSnap 7.12 software (SynGene; Cambridge, England). For
Ir PCR products, three genotype groups were determined based on the following
fragment sizes: 313bp (IRfl/fl), 279bp (IR+/+), or 313bp and 279bp (IRfl/+). In addition, the
presence of a 268bp fragment in MIPCreERT PCR products marked the presence of
MIPCreERT in mice (Figure 2.1B).

2.3

Tamoxifen preparation and administration18
Tamoxifen (Sigma-Aldrich, St. Louis, MO, USA) was prepared by dissolving in

100% ethanol at 300 mg/mL, and preparation of injectable tamoxifen was done by
heating the 300 mg/mL solution to 60 ⁰C and diluting to 30 mg/mL in corn oil (SigmaAldrich, St. Louis, MO, USA).
For fetal studies, a single dose of tamoxifen at 6 mg per 40g of body weight (Hayashi et
al. 2002) was administered by intraperitoneal (i.p.) injection to pregnant female mice at
e13 (Figure 1.3). On e19, pregnant mice were euthanized by CO2 inhalation. Each fetus
was immediately dissected to obtain tail tissue for genotyping, whereas pancreatic tissue
was processed for protein extraction and morphological analyses.
18

For postnatal studies, the β-cell-specific Ir knockout was induced in 3-4 week old mice
via 3 consecutive days of i.p. tamoxifen injection at 4 mg per 20g of body weight (Figure
1.3). The same dosage of tamoxifen was injected into age-matched control littermates.
Post injection, mice were fed normal chow containing 10% kcal fat up to 24 weeks of
age.
For the high-fat diet study, βIrKO, heterozygous, and control mice at 6 weeks of age (2
weeks after i.p. tamoxifen injection) were fed with high-fat diet containing 60% kcal fat
(D12492, Research Diets, New Brunswick, NJ, USA) for 6 weeks.

2.4

Postnatal glucose metabolic studies19
Since our preliminary results demonstrated that all postnatal female groups

exhibited near identical phenotype and glucose metabolism, females were excluded from
further adult studies. Body weight, fasting blood glucose, and intraperitoneal glucose
tolerance tests (IPGTT) were performed at 4, 8, and 20 weeks post-tamoxifen injection
(at 8, 12, 24 weeks of age, respectively) in βIrKO, heterozygous, and control mice on
normal chow diet. In addition, glucose-stimulated insulin secretion (GSIS) was
performed at 8 weeks post-tamoxifen injection, and intraperitoneal insulin tolerance test
(IPITT) was performed at 20 weeks post-tamoxifen injection. All metabolic experiments
were also completed in experimental groups treated with 6 weeks of high-fat diet at 8
weeks post-tamoxifen injection, a time-point matched to the normal chow diet groups.
For the IPGTT, following a 16 hour fast, glucose [D-(+)-glucose; dextrose; SigmaAldrich Canada Co., Oakville, ON, CA] was administered through i.p. at a dosage of 2
mg/g of body weight, and blood glucose levels were examined at 0, 15, 30, 60, 90 and
120 minutes after injection. Area under the curve (AUC) was used to quantify glucose
responsiveness and data are expressed as units of ([mmol/l] x min) (Allison et al. 1995,
Krishnamurthy et al. 2007).
For the IPITT, following a 4 hour fast, human insulin (Humalin, Eli Lilly, Toronto,
Ontario, Canada) at 1 U/kg of body weight was injected intraperitoneally, and blood
19

glucose levels were measured at 0, 15, 30, 60 and 120 minutes (Krishnamurthy et al.
2007, Feng et al. 2013).
For the GSIS, following a 16 hour fast, blood samples (~50l) were collected before (0
minutes) and after glucose loading at 5 and 35 minutes via the tail vein. Each sample was
centrifuged and supernatant was stored in -20 oC. Insulin secretion levels were assessed
by an ultrasensitive enzyme-linked immunosorbent assay (ELISA) (Krishnamurthy et al.
2007, Feng et al. 2013).

2.5

Pancreatic islet isolation20
Islet isolation was performed at 20 weeks post-tamoxifen injection (24 weeks of

age) under normal chow diet groups and at 8 weeks post-tamoxifen injection (12 weeks
of age) under high-fat diet groups. In brief, the bile duct was sutured closed to prevent
injecting into the duodenum, and the pancreas was infused with 3 mL of collagenase V (1
mg/mL, Sigma) through the common bile duct. The inflated pancreas was excised and
placed into a 15 mL BD Falcon tube with 3 mL of cold dissociation buffer (Hank's
balanced salt solution with HEPES, 0.6% g/mL), then incubated in a 37 oC water bath for
30 minutes. Dissociated pancreatic fragments were washed with HBSS washing buffer to
stop enzyme activity. The islet purification was completed using a Ficoll gradient with
purity at ~80%, as described previously (Wang et al. 2004), and processed for protein
extraction.

2.6

Insulin enzyme-linked immunosorbent assay (ELISA)21
Islet insulin content was measured using a mouse ultrasensitive insulin ELISA

kit (ALPCO, Salem, NH, USA) with a sensitivity of 0.15 ng/mL, according to the
manufacturer’s instructions. Insulin release was expressed as ng/mL. Insulin content at
each

time

point

was

measured

using

a

Multiskan

Spectrum

spectrophotometer (Thermo Electron Corp., Waltham, MA, USA).
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microplate

2.7

Tissue processing, immunohistology, and TUNEL22
Dissected fetal or adult pancreata were fixed in 4% paraformaldehyde (PFA)

(Fisher Scientific Company; Ottawa, ON, Canada) at 4 °C overnight. Tissues were then
washed with 1x PBS and processed through a series of increasing ethanol concentrations,
toluene, and wax using an automatic tissue embedding machine (Shandon CitadelTM
Tissue Processor, Citadel 1000, Thermo Electron Corporation; Waltham, MA, USA).
Subsequently, embedded pancreatic tissue blocks were cut into 2-4 µm thick sections
with microtome (Leica RM2245, Leica Biosystems).
After overnight incubation at 37 °C, tissue sections were rehydrated through a series of
xylene washes followed by decreasing ethanol concentrations (100% to 70%). For the
staining of nuclear transcription factors, sections were pretreated with citrate antigen
retrieval solution (pH 6.0) and heated in microwave for 20 min. Blocking solution with
10% normal goat serum (Invitrogen; Frederick, MD, USA) was applied for 30 min at
room temperature to block non-specific antibody binding. Immunofluorescence staining
was performed with appropriately diluted primary antibodies (Table 1) incubated
overnight at 4 °C. Afterwards, diluted (1:50) fluorescently-labelled secondary antibodies
conjugated with either fluorescein isothiocyanate (FITC) or tetramethyl rhodamine
isothiocyanate (TRITC)(Jackson Immunoresearch Laboratories; West Grove, PA, USA)
that was reactive to the selected primary antibody were applied (Table 1). Cell nuclei
were briefly counterstained with diluted (1:1000) 4'-6'-diamidino-2-phenylindole (DAPI)
(Sigma-Aldrich, St. Louis, MO, USA). Cover slips were secured to slides and stored at 20 °C in the dark. Either primary or secondary antibody was excluded from staining for
negative controls.
To examine islet IGF1, IGF2, and MafA levels, immunohistochemical staining was used
with the streptavidin-biotin horseradish peroxidase complex and developed with
aminoethyl carbazole substrate kit (Invitrogen, Burlington, ON, Canada).
Immunohistochemical sections were counterstained with hematoxylin.
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Apoptotic β-cells were identified using the terminal deoxynucleotidyl transferase dUTP
nick end-labeling (TUNEL) assay. Pancreatic sections were pretreated in 20 μg/mL
proteinase K for 10 min at room temperature. TUNEL staining was carried out with 1:10
dilution of enzyme solution in label solution of the In Situ Cell Death Detection Kit
(Roche Applied Science, Quebec City, QC, Canada).
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Table 1: List of Antibodies used for Immunostaining and Western-Blot Analyses
Primary Antibodies

Dilution

Company

Anti-Akt

Rabbit polyclonal

1:3000*

Cell Signaling (Temecula, CA, USA)

Anti-Calnexin

Mouse monoclonal

1:1500*

BD Biosciences (Missasauga, ON,
CA)

Anti-Caspase 3

Rabbit polyclonal

1:1000*

Cell Signaling (Temecula, CA, USA)

Anti-cleaved Caspase-3
(Asp175)

Rabbit polyclonal

1:200 /
1:1000*

Cell Signaling (Temecula, CA, USA)

Anti-GAPDH

Rabbit polyclonal

1:2000*

Santa Cruz Biotechnology (Santa
Cruz, CA, USA)

Anti-Glucagon

Rabbit polyclonal

1:50

Santa Cruz Biotechnology (Santa
Cruz, CA, USA)

Anti-Glut-2

Rabbit Polyclonal

1:100

Chemicon (Temecula, CA, USA)

Anti-IGF1

Rabbit polyclonal

1:200

Abcam (Cambridge, MA, USA)

Anti-IGF2

Rabbit polyclonal

1:200 /
1:1000*

Abcam (Cambridge, MA, USA)

Anti-Insulin

Guinea pig
polyclonal

1:50 /
1:1000*

Zymed (San Francisco, CA, USA)

Anti-Insulin Receptor

Mouse monoclonal

1:200 /
1:1000*

Millipore (Temecula, CA, USA)

Anti-Islet-1

Mouse monoclonal

1:100

DSHB (University of Iowa, Iowa
City, IA, USA)

Anti-Ki67

Rabbit polyclonal

1:100

Abcam (Cambridge, MA, USA)

Anti-MafA

Rabbit polyclonal

1:100

Bethyl Laboratory (Montgomery,
TX, USA)

Anti-Nkx6.1

Mouse monoclonal

1:100

DSHB (University of Iowa, Iowa
City, IA, USA)

Anti-p53

Mouse monoclonal

1:2000*

Cell Signaling (Temecula, CA, USA)

Anti-pan-Cytokeratin

Mouse monoclonal

1:50

Santa Cruz Biotechnology (Santa
Cruz, CA, USA)
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Anti-Pdx-1

Rabbit polyclonal

1:800

Dr. Wright (University of
Vanderbilt, Nashville, TN, USA)

Anti-PECAM-1

Rabbit polyclonal

1:50

Santa Cruz Biotechnology (Santa
Cruz, CA, USA)

Anti-phospho-Akt
(Ser473)

Mouse monoclonal

1:2000*

Cell Signaling (Temecula, CA, USA)

Anti-phospho-p53
(Ser15)

Rabbit polyclonal

1:1000*

Cell Signaling (Temecula, CA, USA)

Anti-Vegf-a

Rabbit polyclonal

1:100 /
1:1000*

Abcam (Cambridge, MA, USA)

Anti-β-actin

Mouse monoclonal

1:5000*

Sigma-Aldrich (St. Louis, MO,
USA)

Horseradish peroxidaselinked secondary
antibodies

Broad Spectrum

1:1 (no
dilution)

Invitrogen (Burlington, ON, CA)

Anti-mouse secondary
antibody

Goat Polyclonal

1:50

JRL (West Grove, PA, USA)

Anti-rabbit secondary
antibody

Goat Polyclonal

1:50

JRL (West Grove, PA, USA)

Secondary Antibodies

*

dilution factor applied to western blot analysis. DSHB, Developmental Studies
Hybridoma Bank; JRL, Jaskcon Immunoresearch Laboratories.
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2.8

Morphometric analysis23
Images of stained tissue sections were obtained and islet morphologies were

blindly analyzed with Image-Pro Plus software (MediaCybernetics; Rockville, MD,
USA). An islet was defined as a dense cell cluster containing at least 3 insulin+ cells. Islet
number (density) was calculated by total number of islets divided by the total area of the
pancreas section. For islet size distribution, every individual islet size was measured and
grouped into different size classes, and expressed as a percentage of the total number of
islet per section. To quantify total islet, α- (glucagon+) and β-cell (insulin+) area, every
islet in sections from all groups were all manually traced and measured with a minimum
of four pancreata per age group per experimental group, then α- and β-cell masses were
calculated using previously described methods (Wang et al. 1994). In brief, β-cell mass
(mg) = (β-cell area * pancreas mass)/pancreas area.
The levels of transcription factors (Pdx-1, Nkx6.1, Islet-1, MafA) localized in β-cells
were determined by double immunofluorescence staining and quantified using the
manual cell counter function in the Image-Pro Plus software. Insulin+ cells positively
stained for transcription factors are normalized to the total number of insulin+ cells per
islet and expressed as a percentage. The percentage of Ki67 localized in β-cell nuclei was
determined from at least 12 random islets per pancreatic section, where a minimum of
five pancreata per experimental group was analysed.
Islet capillary area was imaged with anti-mouse platelet endothelial cell adhesion
molecule (PECAM-1) staining, then manually traced for every islet per section. Islet
capillary density, capillary area per islet, and average islet capillary size was measured to
determine the proportion of vessels present in the islet area. Islet capillary density was
calculated by total number of capillary divided by total islet area. Capillary area per islet
is expressed as a ratio of the total islet capillary area to the islet area. Average islet
capillary size was determined by dividing the sum of individual islet capillary area by the
total number of islet capillaries present in each section. A minimum of five pancreata per
experimental group was analysed.
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Pan-cytokeratin (pan-CK) staining was performed to demonstrate the presence of
epithelial ducts cells within or adjacent to pancreatic islet clusters. The number of panCK+ cells co-localized with Pdx-1 were expressed as a percentage of total number of panCK+ cells per section area. A minimum of five pancreata per experimental group was
analysed.

2.9

Protein extraction and western blot analyses24
Fetal pancreata and isolated islets from postnatal groups were sonicated in

Nonidet-P40 lysis buffer (Sigma-Aldrich; St Louis, MO, USA) and placed on ice for 30
min. Samples were centrifuged at 15871 x g for 20 min at 4 °C, and supernatant was
subsequently collected and stored in -80 °C freezer for protein assay and western blot
analysis. Protein concentrations were measured with the Bradford dye protein assay (BioRad Laboratories; Missisauga, ON, Canada). The protein assay standards were prepared
from bovine serum albumin (BSA) at increasing concentrations of 0, 0.05, 0.1, 0.2, 0.3,
0.4, and 0.5 mg/mL. 10 μL of each standard and 1 μL of sample protein solution was
loaded into micro titer plate in duplicate and mixed with colorimetric dye. Following 20
min incubation in room temperature on a shaker, assay reading was performed at 595 nm
with Multiskan spectrum spectrophotometer (Thermo Scientific).
Equal amounts of protein lysate were prepared (10-20 μg) for each western blot, and
separated by either 5, 7.5, or 10% sodium dodecyl sulphate–polyacrylamide gel
electrophoresis (SDS-PAGE). A constant voltage of 40V initially separated samples until
migration through the stacking gel was complete, then was increased to 80V until the dye
flowed through the bottom. Protein samples were then wet transferred to a nitrocellulose
membrane (Bio-Rad Laboratories; Mississauga, ON, Canada) with transfer buffer
containing glycine (192 mM), Tris (25 mM), and methanol (20 % v/v), and transferred at
a constant current of 250 mA for 2 hours in an ice bucket. Membranes were briefly
stained with Ponceau S stain to confirm proper protein transfer. After washing in Tris
buffered-saline containing 0.1 % Tween-20 (TBST), membranes were incubated in 5%
non-fat dry milk with TBST at room temperature for 1-2 hours. Membranes were then
incubated with appropriately diluted primary antibodies overnight at 4 °C or 1 hour at
26

room temperature (Table 1), washed with TBST, and incubated in secondary antibody at
room temperature for 1 hour. Membranes were washed in TBST after secondary antibody
and proteins were visualized with ECLTM-Plus Western Blot detecting reagents
(PerkinElmer; Waltham, MA, USA), and imaged with a Versadoc Imaging System (BioRad Laboratories; Mississauga, ON, Canada) using Quantity One software (Bio-Rad
Laboratories; Missisauga, ON, Canada). Densitometric analyses of images were
completed with Image Lab 3.0 software (Bio-Rad Laboratories; Missisauga, ON,
Canada) and data were normalized to appropriate loading controls.

2.10 Statistical analysis25
Data is presented as means ± SEM. Statistical analyses were performed using
either one-way ANOVA and Bonferroni’s multiple comparison post hoc tests or
Student’s unpaired t-test with GraphPad Prism 6 (GraphPad Software; La Jolla, CA,
USA). Differences in results were considered statistically significant when p < 0.05.
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Chapter 3 - Results26
3.1 Verification of β-cell-specific Ir knockout in fetal βIrKO
mice27
We first tested the β-cell tissue specificity of the MIP expression by crossing
MIPCre mice with the B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J reporter strain, which
expresses the red fluorescence protein (dTomato) after breeding with MIPCre mice. The
Cre recombinase expression in tissue-specific MIPCre mice will excise the LoxP-stopLoxP signal, which is present 5' to the dTomato, leading to activation and expression of
the dTomato reporter as red fluorescence observed under a fluorescence microscope. In
contrast to MIPCre– control mice, MIPCre+ mouse pancreatic islets expressed red
fluorescence in freshly isolated islets (Figure 3.1A).
To verify the β-cell Ir knockout in the fetal pancreas, western blot analysis was
performed on fetal pancreata collected at e19. A significant knockdown of IR protein
levels in βIrKO pancreata was observed in comparison to control groups (Figure 3.1B).
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Figure 3.1. Confirmation of β-cell specific Ir knockout
(A) dTomato (red) reporter gene is expressed only when Cre recombinase (MIPCre+)
excises the stop codon upstream of the reporter gene. While no fluorescence was detected
in brain or other tissues, the presence of red fluorescence in β-cells confirms the
specificity of MIP-driven Cre recombinase expression in pancreatic β-cells. (B) Western
blot analysis demonstrated a significant reduction of IR protein levels in fetal βIrKO
pancreata relative to controls (n = 3-4). Representative blotting image is shown. White
bar, control group; black bar, βIrKO group. Data are expressed as means ± SEM. *p <
0.05.
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3.2

Fetal βIrKO mice exhibit a hyperplastic islet growth

response28
When fetal pups were dissected at e19, no significant differences in body weight
and blood glucose levels were observed between βIrKO and control groups. In order to
unravel the role of β-cell IR activity during fetal pancreatic development, we performed
immunofluorescence staining to characterize β-cells and overall islet morphology
(Figure 3.2A). Although not statistically significant, morphometric analyses suggest an
increased islet density (islet number/mm2) in fetal βIrKO pancreata (Figure 3.2B). In
βIrKO mice, the percent of islet area (percentage of total islet/ total pancreas area; Figure
3.2C), mean islet area (μm2) (Figure 3.2D), and percent β-cell area (percentage of total
insulin+/ total pancreas area; Figure 3.2E) were significantly increased. Alternatively, αcell area (percentage of total glucagon+/ total pancreas area) showed no change in βIrKO
compared to control pancreata (Figure 3.2F).
To further characterize fetal islet morphology, we evaluated various size distributions of
islets in control and βIrKO pancreata. We observed that βIrKO pancreata had a
significantly decreased number of small islets (< 1000 μm2) and a significantly increased
number of large islets (> 10000 μm2) compared to controls (Figure 3.2G), indicating
relative hyperplastic growth of the islets in βIrKO pancreata. Thus, it appears that
reduction of β-cell-specific IR promotes islet growth through expansion of the β-cells.
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Figure 3.2. Islet growth in fetal βIrKO pancreata
(A) Representative immunofluorescence image depicting the expansion of β-cells within
fetal βIrKO pancreata compared to controls. Scale bar: 200 μm. Morphometric analysis
of (B) number of islets per mm2, (C) percent islet area, (D) mean islet area, (E) percent βcell area, and (F) percent α-cell area relative to whole pancreas area. (G) Quantification
of different islet sizes shows that βIrKO pancreata had a significantly greater percentage
of large islets (islets > 10 000 μm2) and significantly reduced percentage of small islets
(islets < 1 000 μm2). White bars, control group; black bars, βIrKO group. Data are
expressed as means ± SEM (n = 5-6). *p < 0.05, **p < 0.01.
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3.3

Increased β-cell proliferation in βIrKO mice29
To investigate the molecular mechanisms contributing to islet growth response in

βIrKO mice, we first assessed β-cell proliferation using double immunofluorescence
staining for insulin and Ki67 proliferation marker (Figure 3.3A). We quantified the
percentage of insulin+ cells with nuclear localization of Ki67. βIrKO pancreata had
significantly greater number of proliferating insulin+ cells compared to controls (p <
0.001; Figure 3.3B). In addition, we sought to determine if the increased β-cell
proliferation in βIrKO pancreata was due to increased islet neogenesis. During islet
development, islet neogenesis initiates from the pancreatic ductal epithelium and are
always Pdx-1 positive, which is a marker for early β-cell differentiation. Therefore, we
assessed the percentage of pan-CK+ epithelial ducts cells (within or adjacent to pancreatic
islet clusters) positively stained for the Pdx-1 transcription factor, as an indicator for islet
neogenesis. There was no significant difference in the percentage of pan-CK+/Pdx-1+
cells between βIrKO (~6.5%) and control (~8.3%) pancreata (Figure 3.4). Taken
together, these results suggest that the islet hyperplastic growth seen in βIrKO mice is
likely attributed to the increased replication of pre-existing β-cells, rather than ductal-toislet neogenesis.
Next, we determined if decreased apoptosis of developing islet cells also contributes to
the islet growth response seen in βIrKO mice. TUNEL staining did not show a difference
in the percentage of insulin+ cells with nuclear TUNEL positivity in βIrKO pancreata
relative to control mice (Figure 3.5). Similarly, western blot analyses were unable to
detect a difference in cleaved caspase-3 levels between βIrKO and control pancreata
(Figure 3.6C). Therefore, apoptosis does not appear to play an important role in islet
hyperplasia observed in fetal βIrKO pancreata.
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Figure 3.3. Enhanced β-cell proliferation in fetal βIrKO pancreata
(A) Representative double immunofluorescence images demonstrating a significantly
increased percentage of insulin+ cells with nuclear Ki67 staining in βIrKO islets
compared to control. White arrows indicate cells positive for Ki67. Scale bar: 50 μm. (B)
Quantification of immunofluorescence images by cell counting show a significant
increase of Ki67 positive β-cells in βIrKO islets relative to controls. White bar, control
group; black bar, βIrKO group. Data are expressed as means ± SEM (n = 5). ***p <
0.001.
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Figure 3.4. Similar levels of islet neogenesis from epithelial ducts in fetal βIrKO and
control pancreata
(A) Representative double immunofluorescence images of fetal islets with adjacent
epithelial duct cells, marked by pan-CK staining (green), and Pdx-1 (red). Pdx-1+ duct
cells indicate potential islet neogenesis. White arrows indicate Pdx-1 nuclear localization
in duct cells. Scale bar: 50 μm. (B) Quantification of the percentage of epithelial duct
cells (adjacent to islets) positive for Pdx-1. White bar, control group; black bar, βIrKO
group. Data are expressed as means ± SEM (n = 5).
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Figure 3.5. No change in cell apoptosis in fetal βIrKO pancreata
(A) Double immunofluorescence images demonstrating similar levels of insulin+ cells
with nuclear TUNEL staining in βIrKO islets compared to control. White arrows indicate
nuclear localization. Scale bar: 50 μm. (B) Quantification of the percentage of insulin+
cells with nuclear TUNEL staining. Data are normalized to control and expressed as
means ± SEM (n = 4-5).
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Figure 3.6. Downstream IR signalling pathway analysis
Western blot analyses demonstrated that βIrKO had significantly upregulated levels of
(A) phospho-S473 Akt (n = 4), and significantly downregulated levels of (B) phosphoS15 p53 (n = 3-4). (C) However, the apoptotic activity, marked by cleaved caspase-3,
was not different between fetal βIrKO and controls. Representative blotting images are
shown. White bars, control group; black bars, βIrKO group. Data are normalized to
control and expressed as means ± SEM. *p < 0.05.
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3.4

Fetal βIrKO islet cells present enhanced replication and pro-

survival signalling pathway activity30
To account for increased islet replication and growth, we investigated signalling
pathways involved in cell survival. Akt is part of the IR downstream signalling cascade
and has an influential role in the regulation of β-cell replication. Fetal βIrKO exhibited a
robust increase in phospho-Akt (S473) levels compared to control pancreata (p < 0.05;
Figure 3.6A). Previous studies have shown that activated Akt can prevent apoptosis by
indirectly inhibiting downstream p53 activity (Mayo et al. 2001, Wrede et al. 2002). In
agreement with increased phosphorylation of Akt in βIrKO mice, phospho-p53 (S15), a
marker for apoptosis, was significantly reduced in βIrKO pancreata relative to control (p
< 0.05; Figure 3.6B). These results suggest that reduced β-cell IR levels may elicit an
adaptive signalling mechanism through the homologous IGF1R signalling pathway. To
explore this further, we investigated the levels of the IGF1 and IGF2 ligands. In
particular, IGF2 has been demonstrated to be highly localized to islets during fetal
development, and it has a relatively high affinity for both IGF1R and IR. Furthermore,
studies suggest a close relationship between IGF2 levels and β-cell expansion.
Immunohistochemical staining showed localization of IGF2 in fetal pancreatic islets with
a relatively high density of staining observed in the βIrKO islets (Figure 3.7A). On the
other hand, IGF1 levels were low in fetal islets (Figure 3.7B). Further western blot
analyses revealed a significantly increased IGF2 levels in fetal βIrKO pancreata
compared to fetal control pancreata (p < 0.005; Figure 3.7C). These data imply that fetal
βIrKO elicits a signalling pathway network adaptation that involves enhanced IGF2
production and activity through homologous receptors, with corresponding increases and
decreases in Akt and p53 activity, respectively. Overall, this signalling cascade likely
promotes β-cell proliferation.
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Figure 3.7. Strong localization and increased levels of IGF2 in fetal βIrKO
pancreata
(A) Representative immunohistochemical staining showing strong IGF2 localization
(brown) in pancreatic islets. (B) IGF1 levels were very low in fetal pancreata. Nuclei
were counterstained with hematoxylin. Scale bar: 50 μm. (C) Western blot analyses
showed that fetal βIrKO pancreata had significantly upregulated IGF2 protein levels
relative to control (n=5-13). Representative blotting image is shown. White bar, control
group; black bar, βIrKO group. Data are normalized to control and expressed as means ±
SEM. *p < 0.01.

45

3.5

Increased vascularization in fetal βIrKO pancreatic islets31
A previous study has demonstrated a correlation between fetal islet compensatory

growth response and increased islet vascularization in insulin-null mice (Duvillie et al.
2002). We also assessed the possibility that increased vascularization could be another
contributing factor to the hyperplastic islets observed in fetal βIrKO mice. Islet
vasculature was assessed by quantifying the percentage of islet PECAM-1 area over total
islet area, mean vessel area, and mean islet vessel density in pancreatic sections (Figure
3.8A). Immunofluorescence staining demonstrated a significant increase in the percent of
PECAM-1 area/total islet area (Figure 3.8B) and islet vessel density in βIrKO mice
relative to controls (Figure 3.8C). However, the average islet capillary size was similar
amongst all experimental groups, indicating increased islet angiogenesis, as opposed to
enlargement of pre-existing capillaries (Figure 3.8D). In accordance with these findings,
fetal βIrKO pancreata had significantly elevated Vegf-a levels, as demonstrated by
immunofluorescence (Figure 3.9A) and western blot (Figure 3.9B). These results
supported our finding of enhanced IGF2 levels in βIrKO pancreata since IGF2 could
promote islet vascularization via upregulation of Vegf-a levels.
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Figure 3.8. Fetal βIrKO display increased vascularization
(A) Representative double immunofluorescence images show increased vascularization
(green) in pancreatic islets in βIrKO mice. Scale bar: 50 μm. Quantification of
immunofluorescence images demonstrates that (B) the percent of PECAM-1 area/islet
area (n = 4-5) and (C) islet vessel density (n = 4-5) were significantly increased in βIrKO
pancreata compared to control. (D) Average islet capillary size was similar between the
groups. White bars, control group; black bars, βIrKO group. Data are expressed as means
± SEM. *p < 0.05, **p < 0.01.
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Figure 3.9. Increased Vegf-a levels in fetal βIrKO pancreata
(A) Representative double immunofluorescence images demonstrating increased Vegf-a
(green) levels in insulin+ cells (red) of pancreatic islets in βIrKO animals. Scale bar: 50
μm. (B) Western blotting shows that corresponding protein levels of Vegf-a was
significantly upregulated in βIrKO pancreata relative to controls (n = 3-5). Representative
blotting images are shown. White bar, control group; black bar, βIrKO group. Data are
normalized to control and expressed as means ± SEM. **p < 0.01.
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3.6

β-cell-specific Ir knockout at the second transition of

pancreatic development does not affect β-cell identity32
To determine the role of β-cell IR activity in β-cell differentiation and identity
during fetal pancreatic development, immunofluorescence and immunohistochemistry
staining was performed on fetal pancreatic tissue sections. These morphological analyses
characterize the potential for altered transcription factor levels, where normal expression
is critical for the maintenance and development of β-cell differentiation and function.
Qualitative observations revealed that approximately all β-cells (identified by insulin
positivity) had nuclear Pdx-1 (Figure 3.10A), Nkx6.1 (Figure 3.10B), Islet-1 (Figure
3.10C), and MafA (Figure 3.10D) in both βIrKO and control mice. Previously, glucose
transporter 2 (Glut-2) has been associated with glucose-dependent insulin secretion and
β-cell development, and thus, we examined the levels of Glut-2 in the fetal islets of all
groups. Although βIrKO islets were generally larger in size, they possessed similar
intensity and membrane-localization of Glut-2 in the insulin+ cells compared to control
pancreata (Figure 3.10E). Therefore, it appears that β-cell-specific Ir knockout during
fetal pancreatic development does not alter β-cell identity or function.
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Figure 3.10. Fetal βIrKO islets expressed TFs necessary for β-cell identity and
function
Representative double immunofluorescence images showing that insulin+ cells (red) of
both βIrKO and control pancreata display nuclear localization of transcription markers
(all represented as green) critical for β-cell identity and function (A) Pdx-1, (B) Nkx6.1,
(C) Islet-1. (D) Immunohistochemical staining demonstrates similar levels of MafA in
both experimental groups. (E) Glut-2 immunofluorescence staining demonstrating similar
levels in both βIrKO and control pancreata. Scale bar: 50 μm.

53

3.7

Postnatal βIrKO confirmation33
Since the exocrine compartment of the pancreas also expresses insulin receptors

on acinar cell membranes, we carefully isolated the pancreatic islets from the whole
pancreas to verify the β-cell-specific Ir knockout in the adult mice experimental groups.
Using western blot analysis, we observed a ~50% knockdown of IR protein levels in
βIrKO pancreata in comparison to control groups (Figure 3.11). However, the
heterozygous group displayed highly varying levels of IR protein.
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Figure 3.11. Western blot analysis of β-cell Ir knockout efficiency
Western blot analysis of isolated islets from postnatally induced βIrKO male mice
demonstrated a significant reduction in IR protein levels in βIrKO pancreata relative to
controls (n = 6). Representative blotting image is shown. White bar, control group; black
bar, βIrKO group. Data are normalized to control and expressed as means ± SEM. *p <
0.05.
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3.8

Phenotypical analysis of postnatally induced β-cell specific Ir

knockout mice34
Postnatal breeding produced experimental βIrKO mice with MIPCreERT+;IRfl/fl,
heterozygous βIrKO mice with MIPCreERT+;IRfl/+, and control mice that consisted of
genotypes MIPCreERT–;IRfl/fl and MIPCreERT+;IR+/+. Based on previous reports, and
due to lack of differences in our preliminary in vivo metabolic studies between
heterozygous βIrKO and control groups, the heterozygous βIrKO group was omitted at 8
and 20 weeks post-tamoxifen time points. The body weights of male βIrKO mice did not
significantly differ at 4, 8, and 20 weeks post-tamoxifen when compared to the control
and heterozygous groups, indicating that β-cell IR does not affect the gross phenotypes of
these mice (Figure 3.12A). Similarly, 16 hour overnight fasting blood glucose levels
were not different between the experimental groups at all ages analyzed (Figure 3.12B).
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Figure 3.12. Phenotypic analysis of postnatal tamoxifen-induced βIrKO mice
(A) Fasting body weights at 0, 4, 8, and 20 weeks post-tamoxifen injection in male mice
(n = 5-10). (B) Overnight (16hrs) fasted blood glucose levels at 4, 8, 20 weeks posttamoxifen injection in male mice (n = 5-10). DOI stands for “date of tamoxifen
injection”. White bar, control group; black bar, βIrKO group. Data are expressed as
means ± SEM.
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3.9

Metabolic studies of postnatally induced βIrKO mice35
Glucose tolerance (GTT), insulin tolerance (ITT), and glucose-stimulated insulin

secretion (GSIS) tests were performed at various ages to determine the effects of β-cellspecific Ir knockout on glucose metabolism. No significant changes in IPGTT were
observed in male βIrKO when compared to control and heterozygous groups at 4 weeks
post-tamoxifen (Figure 3.13A). At 8 weeks post-tamoxifen, βIrKO mice showed no
statistically significant differences in AUC in comparison with experimental groups,
despite the relatively higher peak at 60 and 90 minutes after i.p. injection of glucose
(Figure 3.13B). In addition, in vivo GSIS at 8 weeks post-tamoxifen injection
demonstrated similar insulin secretion responses between βIrKO and control groups
(Figure 3.13C). When these mice were aged to 20 weeks post-tamoxifen, both βIrKO
and control mice exhibited higher glucose levels at 60, 90, and 120 minutes following
glucose injection when compared to experimental mice at 4 and 8 weeks post-tamoxifen
injection. However, IPGTT of βIrKO did not significantly differ from the control mice
(Figure 3.14A), suggesting that these β-cells are still functional when Ir knockout is
induced after birth. This age-dependent increase in glucose intolerance is most likely due
to the increased body weight and genetic composition of the B6 mice (Almind et al.
2004).
To determine whether insulin resistance plays a role in these mice, IPITT was performed
at 20 weeks post-tamoxifen injection. Both βIrKO and control mice exhibited normal
metabolic response to a dose of insulin, demonstrating that these mice did not develop
insulin resistance (Figure 3.14B).
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Figure 3.13. Adult βIrKO mice demonstrate normal glucose metabolism at 4 and 8
weeks after Ir knockout
Overnight (16hrs) fasted IPGTT at (A) 4 weeks and (B) 8 weeks post-tamoxifen in βIrKO
and control groups. Glucose responsiveness of the corresponding experimental groups is
shown as a measurement of AUC of the IPGTT graphs (n = 6-7). (C) Overnight fasted
(16hrs) in vivo glucose-stimulated insulin secretion at 8 weeks post-tamoxifen injection
shows a lack of difference between the experimental groups (n = 6-7). White bars, control
group; black bars, βIrKO group. Data are expressed as means ± SEM. *p < 0.05.
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Figure 3.14. Aged experimental groups appear to exhibit similar levels of glucose
intolerance
At 20 weeks post-tamoxifen injection, (A) overnight (16hrs) fasted IPGTT and (B) 4
hours fasted IPITT were completed (n = 6-7). Glucose or insulin responsiveness of the
corresponding experimental groups is shown as a measurement of AUC of the IPGTT
and IPITT graphs. White bars, control group; black bars, βIrKO group. Data are
expressed as means ± SEM.
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3.10 Pancreas morphology at 20 weeks post-tamoxifen injection36
Since βIrKO and control groups both exhibited glucose intolerance compared to
earlier age groups, morphometric analyses of the pancreas were performed after 20 weeks
post-tamoxifen to further examine the effects of β-cell-specific IR deficiency under
metabolic stress. At 20 weeks post-tamoxifen injection, mice were euthanized and
pancreas weights were measured, but no significant difference was observed between
βIrKO and control groups (Figure 3.15A). There was no difference in islet number per
mm2 (Figure 3.15E) and islet size distribution (Figure 3.15B) between βIrKO and
control groups. Quantitative analysis of β-cell mass (Figure 3.15C) and α-cell mass
(Figure 3.15D) further showed no changes between the experimental groups.
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Figure 3.15. No differences in pancreatic morphology were observed between βIrKO
and control mice
Representative pancreatic islets are shown, with glucagon+ α-cells (green) and insulin+ βcells (red). Male mice were dissected at 20 weeks post-tamoxifen injection. Pancreatic
morphological analysis of (A) pancreas weight, (B) islet size distribution, (C) β-cell
mass, (D) α-cell mass, and (E) islet number/mm2 show similar islet morphology between
experimental groups (n = 4). White bars, control group; black bars, βIrKO group. Data
are expressed as means ± SEM.
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3.11 Under high-fat diet, postnatally induced βIrKO mice display
comparable glucose metabolism to control mice37
Previous studies have suggested the importance of β-cell IR on postnatal islet
compensatory growth in response to high-fat diet (Okada et al. 2007). We further
investigated the effect of high-fat stress on postnatally induced β-cell-specific Ir
knockout mice. Interestingly, after 6 weeks on high-fat diet, all study groups (βIrKO,
heterozygous, and control) were similar in terms of body weight and fasting blood
glucose, and they were not significantly different from mice on normal chow (Figure
3.16). Next, we sought to determine whether high-fat diet stress could accelerate β-cell
dysfunction in βIrKO mice. When compared to same aged mice under chow diet (Figure
3.13B), all experimental groups demonstrated higher IPGTT levels, indicating an early
onset of high-fat diet induced diabetes (Figure 3.17A). However, IPGTT results for
βIrKO, heterozygous, and control mice were not significantly different from each other,
further questioning the necessity of postnatal IR in β-cell maintenance and function. In
addition, IPITT revealed normal insulin sensitivity in all study groups under high-fat diet
(Figure 3.17B).
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Figure 3.16. Phenotypes of experimental male mice after 6 weeks of high-fat diet
(A) Weekly body weights monitored for 6 weeks on high-fat diet. (B) Body weight and
(C) overnight (16hrs) fasted blood glucose levels at the end of high-fat diet in βIrKO,
heterozygous, and control groups (n = 6-9). Data are expressed as means ± SEM.
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Figure 3.17. Metabolic studies at 8 weeks post-tamoxifen in male mice after 6 weeks
on a high-fat diet
(A) Overnight (16hrs) fasted IPGTT (n = 6-8), and (B) 4 hours fasted IPITT (n = 3-6)
were performed on all experimental groups. Glucose or insulin responsiveness of the
corresponding experimental groups is shown as a measurement of AUC of the IPGTT
and IPITT graphs. Data are expressed as means ± SEM.
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Chapter 4 - Discussion38
This project examined the in vivo role of β-cell-specific insulin receptor during
different developmental stages using a novel conditional and temporal Ir knockout
model. In contrast to many previous βIrKO that utilized the Cre/loxP system to facilitate
congenital β-cell Ir knockout, our tamoxifen-inducible βIrKO mouse model allowed Ir
knockout at various developmental ages. We demonstrated that β-cell-specific Ir
knockout during the secondary transition of pancreatic development leads to an adaptive
islet growth. The robust increase of β-cell proliferation was associated with significantly
increased IGF2 levels, phospho-Akt activity, and enhanced islet vascularization.
Interestingly, βIrKO after postnatal pancreatic remodelling in 3 week old adult mice
failed to develop age-dependent glucose intolerance phenotype seen in previous studies.
In addition, adult βIrKO, control, and heterozygous groups after 6 weeks of high-fat-diet
stress developed impaired glucose tolerance, but they were indistinguishable from each
other. Taken together, the results from this thesis suggest that the loss of β-cell-specific
IR promotes β-cell replication during embryonic islet development, but IR may not be
required for postnatal β-cell mass maintenance and function.

4.1

Does β-cell-specific Ir knockout affect islet formation during

secondary transition?39
We first confirmed the specificity of the MIPCreERT expression to pancreatic βcells by crossing the MIPCreERT mice with B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J
reporter mice. In addition, western blot analysis of fetal pancreata demonstrated that βcell IR levels were significantly reduced (~75%) in fetal βIrKO mice. Our recombination
efficiency supports previous research demonstrating that 50 to 70% of Cre-recombination
is achieved depending on the tamoxifen dosage (Hayashi et al. 2002).
Similar to previous βIrKO studies, the body weight of newborn pups did not differ
between littermates, indicating overall normal embryonic development (Kulkarni et al.
1999, Okada et al. 2007). Although these studies did not conduct in-depth quantitative
analyses of islet morphology during prenatal stages, they suggested that β-cell IR does
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not play an essential role in fetal islet development and maturation (Kulkarni et al. 1999,
Okada et al. 2007). Contrary to this statement, our results demonstrated a significant
increase in β-cell area, mean and overall islet area when β-cell Ir was knocked out during
the secondary transition. An explanation for this is that we are the first group to induce βcell-specific Ir knockout at embryonic day 13 (e13) instead of congenital β-cell Ir
knockouts seen in previous studies. Since the secondary transition is a period of rapid βcell differentiation, expansion, and maturation, the loss of existing β-cell IR could lead to
an immediate cell adaptation response seen in our βIrKO mice (Habener et al. 2005,
Gunasekaran et al. 2012), implicating that in vivo β-cell-specific Ir knockout phenotypes
are time-dependent. The current study demonstrated that the abrupt loss of IR signalling
in β-cells during islet development, specifically during secondary transition, led to an
islet hyperplastic growth response. Islet hyperplasia seen in fetal βIrKO is consistent with
the congenital insulin knockout mouse model, where the loss of insulin led to increased
islet size, proliferation, and vascularization at e19 (Duvillie et al. 2002). Together, these
findings indicate that the loss of IR signalling has an adaptive stimulatory effect on
prenatal β-cell growth.
To characterize whether islet hyperplasia in fetal βIrKO pancreas is due to either β-cell
proliferation from pre-existing β-cell or neogenesis from progenitors, we examined β-cell
proliferation using immunofluorescent Ki67 staining versus β-cell apoptosis by TUNEL
staining. While TUNEL staining showed relatively similar levels of apoptosis, the
proliferation of β-cells in fetal βIrKO mouse islets were significantly higher than that of
littermate controls. This result indicates that β-cell replication from pre-existing β-cells
likely contributed to islet hyperplasia in fetal βIrKO mice. This data is in agreement with
previous studies that demonstrated β-cell replication starting around e16.5 is responsible
for maintaining β-cell survival throughout postnatal development (Montanya et al. 2000,
Dor et al. 2004). Generally, murine β-cell neogenesis from ductal cells begins at e9 and
remains active for the first few weeks after birth until weaning. In order to determine
whether β-cell neogenesis also contributed to islet hyperplasia, Pdx-1 localization in
ductal cells in both fetal βIrKO and control pancreata were examined. We observed
similar levels of Pdx-1+ ductal cells between the groups, suggesting that fetal β-cell Ir
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knockout may not have affected islet neogenesis. Consistent with our results, Duvillie et
al. (2002) showed enlarged fetal islets in insulin knockout mice without an increase in
islet neogenesis. Therefore, we believe that the islet growth response in fetal βIrKO mice
is likely due to the enhanced β-cell replication, rather than increased levels of islet
neogenesis.
To examine whether fetal βIrKO altered proper β-cell maturation, we investigated
transcription factors that are required for β-cell maturation. It is well documented that
Pdx-1 in β-cells is necessary for insulin synthesis, glucose metabolism, and β-cell
survival (Brissova et al. 2002, Gittes 2008). Similarly, Nkx6.1, MafA, and Islet-1 are
necessary for β-cell differentiation and postnatal function. (Sander et al. 2000, AguayoMazzucato et al. 2011, Ediger et al. 2014). There were similar levels of β-cell nuclear
localization for both fetal βIrKO and control pancreata with Pdx-1, Nkx6.1, MafA, and
Islet-1. In addition, we showed that the levels of Glut-2, a marker for β-cell glucose
sensitivity, did not differ between βIrKO and control pancreas, further suggesting that
these β-cells properly developed and are functional despite the early loss of β-cell IR.

4.2

Could the β-cell-specific Ir knockout promote activity of

homologous signalling pathways?40
We sought to determine the signalling pathways that may contribute to increased
replication of functional β-cells observed in fetal β-cell-specific Ir knockout mice.
Western blot analysis revealed increased phosphorylation of Akt, an important regulator
of β-cell proliferation and anti-apoptotic signalling, in fetal βIrKO pancreata. Similar to
our results, overexpression of Akt in pancreatic β-cells has been associated with increased
β-cell size and total islet mass (Tuttle et al. 2001). In addition, we detected decreased
phosphorylation of the tumor suppressor p53 in βIrKO pancreata relative to control mice.
Congruent with our findings of increased Akt and reduced p53 activity, numerous studies
have suggested that active Akt downregulates p53 in the INS-1 rat insulinoma cell line
and isolated pancreatic islets (Wrede et al. 2002, Feng et al. 2013. Ogawara et al. 2002).
Since p53 plays a key role in the induction of apoptosis and cell cycle arrest, we
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speculate that impaired regulation of cell cycle arrest could also contribute to the
increased β-cell proliferation seen in βIrKO pancreata.
To account for the enhanced Akt activity seen in fetal βIrKO pancreata, we investigated
IGF1 and IGF2 because they have the ability to stimulate both IR and IGF1R (Louvi et
al. 1997, Nakae et al. 2001). During fetal development, IGF2 is strongly localized to
pancreatic islets and is more abundant than IGF1 (Hill et al, 1999). Consistent with this
finding, we showed that IGF1 levels were very low in the fetal pancreas and we conclude
that Akt activity is likely induced by the elevated IGF2 protein levels localized to fetal
βIrKO islets. In agreement with our results, IGF2 overexpressing transgenic mice
exhibited robust islet cell hyperplasia and apoptotic inhibition (Petrik et al. 1999).
Similarly, another group utilized the Goto-Kakizaki diabetic rat model to examine
defective fetal IGF2 production, which led to a reduction in β-cell mass (Calderari et al.
2007). Our results suggest that the loss of fetal β-cell IR leads to an upregulation of IGF2
protein levels in the islets, which signals through the IGF1R to promote Akt-mediated βcell proliferation during fetal development (Figure 4.1). Since our western blot analysis
showed that β-cell-specific Ir was not entirely knocked out, it is also possible that IGF2
exerted its proliferative effects through remaining IR on the β-cells. However, IGF2
levels rapidly diminishes from birth to postnatal day 28 in rats (Hill et al, 1999), so it is of
interest for further experiments to examine whether the increased islet growth seen in
fetal βIrKO pancreas can be sustained neonatally. Interestingly, a recent study
demonstrated that β-cell-specific Igf2 overexpressing adult mice have disrupted islet
structure, islet hyperplasia, and develop glucose intolerance, indicating β-cell dysfunction
(Casellas et al, 2015). Therefore, further experiments are necessary to determine the
consequences of increased prenatal IGF2 levels on neonatal β-cell function.

76

Figure 4.1. Proposed adaptive signalling mechanisms in fetal βIrKO mice
We demonstrated that the tamoxifen-induced loss of β-cell IR during fetal pancreatic
development results in enhanced levels of IGF2. We propose that the IGF2 released from
βIrKO β-cells exerts autocrine/paracrine activation of IGF1 receptors, causing an increase
in Akt phosphorylation/activation and stimulation of downstream signalling pathways.
Resulting upregulated Vegf-a production and secretion contribute to increased
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vascularization. Consequently, enhanced Akt activity combined with increased islet
vascularization promotes β-cell replication, inducing the islet growth response seen in
βIrKO mice.

4.3

Is the level of islet vascularization associated with islet

growth during prenatal life?41
Previous studies have proposed that increased vascularization can promote β-cell
differentiation and replication because the endothelium and its associated blood supply
are essential for the β-cell differentiation and maintenance of β-cell function (Lammert et
al. 2001, Nikolova et al. 2006, Brissova et al. 2006). In our study, βIrKO pancreata
exhibited significantly increased islet capillary area (percent of PECAM-1+ area/islet
area), islet vessel density, and Vegf-a protein levels. Pancreatic β-cells produce Vegf-a to
attract endothelial cells, which form capillaries throughout the islets. Similar to our
results, insulin knockout mice also resulted in a simultaneous increase of β-cell mass and
islet vascularization during fetal development (Duvillie et al. 2002). Therefore, our
results further support the notion that increased islet vascularization promotes islet
growth seen in fetal βIrKO mice. In addition, Duvillie et al. (2002) speculated the
contribution of IGF2 to the islet hyperplasia but did not observe an increase in Igf2
mRNA levels. In contrast, we demonstrated that IGF2 protein levels is increased,
implying that there may be an altered posttranscriptional regulation that stimulates IGF2
protein production. IGF2 can further promote embryonic vasculogenesis by upregulating
Vegf levels (Piecewicz et al. 2012). In many tumours, tumour-derived IGF2 has been
shown to bind to IGF1R, leading to increased Vegf production and subsequent
angiogenesis (Bid et al. 2012, Bid et al. 2013). Taken together, our fetal βIrKO study
suggests that βIrKO knockout in the developing mouse pancreas causes an adaptive
upregulation of IGF2 levels in the islets, which contributes to the observed Akt elevation,
increased Vegf-a protein levels, and subsequent islet vascularization. Together, Akt and
increased islet vascularization stimulate β-cell replication (Figure 4.1).
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4.4

Do postnatally induced β-cell-specific knockout mice exhibit

age-dependent glucose intolerance?42
4.4.1 Recombination efficiency of inducible postnatal β-cell-specific Ir
knockout?43
To better understand the role of β-cell IR exclusively during postnatal life, we
induced β-cell-specific Ir knockout after postnatal pancreatic islet remodelling at 3-4
weeks of age in adult mice. Western blot analysis confirmed a significant reduction of the
β-cell IR protein levels in isolated islets of βIrKO mice compared to controls, but was
only found to be only ~50% reduced. The observed recombination efficiency is mainly
attributed to the tamoxifen dosage that we utilized. The efficiency of the inducible CreloxP recombination in adult mice has been extensively evaluated with various reporter
strains. Previous studies have used various dosages of tamoxifen injection, ranging from
3 consecutive days of 1 mg up to 5 days of 9 mg tamoxifen injection, resulting in a
varying recombination efficiency of up to ~90% (Hayashi et al. 2002, Wicksteed et al.
2010, Reinert et al. 2012, Tamarina et al. 2014). These findings suggest that the
recombination efficiency is tamoxifen dose-dependent, and multiple injections of even
the highest dosage did not lead to any major changes in animal behaviour or
physiological side effects (Hayashi et al. 2002). However, Reinert et al. (2012) observed
incomplete absorption of corn oil vehicle as well as scrotal enlargement in tamoxifen
treated mice, and the consequences of these side effects are unknown. Therefore, we
utilized a lower dosage of 3 consecutive days of 4 mg / 20g of body weight tamoxifen
injection for the postnatally induced βIrKO mice in an attempt to achieve an optimal level
of recombination while avoiding potential side effects. Thus, the insufficient β-cell Ir
knockout could have contributed to the insignificant changes for the phenotypes of βIrKO
mice.

4.4.2 Does postnatal β-cell-specific Ir knockout affect glucose metabolism?44
The overnight fasting blood glucose levels and body weight measured at 4, 8, and
20 weeks post-tamoxifen injection showed no difference between control and βIrKO
79

mice. Previous studies utilizing congenital βIrKO mouse models have found similar
fasting blood glucose results at 2 and 6 months of age (Kulkarni et al. 1991, Ueki et al.
2006). However, unlike our adult βIrKO mice, studies have observed glucose intolerance
in congenital βIrKO mice, suggesting the importance of β-cell IR for glucose metabolism
in adult life. Similar other reports have demonstrated impaired glucose homeostasis in
βIrKO mice as early as 4-5 weeks of age (Ueki et al. 2006, Okada et al. 2007), or
progressive age-dependent glucose intolerance from 2-6 months of age (Kulkarni et al.
1991). Furthermore, previous studies also demonstrated a loss of acute first-phase but
normal second-phase insulin secretion in βIrKO mice at 1 month (Okada et al. 2007) and
3 months of age (Kulkarni et al. 1991). This functional change in insulin secretion was
not observed in our postnatally induced βIrKO mice, which displayed similar glucosestimulated insulin secretion during both 1st and 2nd phases.
The discrepancy between previous studies and our results may be attributed to the
utilization of different promoters to drive β-cell-specific Ir knockout. Former in vivo
βIrKO studies utilized the RIP, which is also actively expressed in the hypothalamus,
leading to ectopic expression of Cre recombinase (Wicksteed et al. 2010). Subsequently,
altered levels of IR in the brain could adversely affect glucose homeostasis. Another
reason for this conflicting finding is the insufficient deletion of β-cell Ir. As we
mentioned above, we only achieved an Ir knockout of ~50% in pancreatic islets,
suggesting that the remaining β-cell IR are able to maintain normal glucose homeostasis.
This is supported by one study that found that global heterozygous Ir knockout mice
retained normal phenotypes and displayed similar levels of glucose tolerance as controls,
whereas null Ir mice quickly died after birth due to severe ketoacidosis (Joshi et al. 1996,
Acili et al. 1996). Taken together, we suggest that β-cells have a plethora of IR, and that a
reduced amount of β-cell IR (~50%) is sufficient for proper β-cell maintenance and
function in postnatal life. Additionally, previous studies have shown that double β-cell Ir
and Igf1r knockout mice exhibit the most severe glucose intolerance and die from severe
ketoacidosis starting at 6 weeks, suggesting that these receptors are able to compensate
for each other to a certain extent (Ueki et al. 2006, Xuan et al. 2010).

80

All the previous studies utilized the same congenital RIP-driven β-cell-specific Ir
knockout model, while we used an inducible MIP-driven β-cell-specific Ir knockout
model where β-cell Ir was knocked out 4 weeks after birth (Ueki et al. 2006, Okada et al.
2007, Kulkarni et al. 1991). By inducing the β-cell Ir knockout around 4 weeks of age,
we allowed proper fetal pancreatic formation, including the undisturbed completion of
the third transition in pancreatic development, which spans from embryonic day 18 to
postnatal day 21. The third transition, also defined as the pancreatic remodelling period,
is an important stage of β-cell proliferation, apoptosis, and maturation (Kaung 1994,
Scaglia et al. 1997). Previous congenital βIrKO mice lacked β-cell IR throughout
essential prenatal pancreatic development and postnatal remodelling, causing these mice
to exhibit early age-dependent β-cell dysfunction. In contrast, we induced β-cell Ir
knockout in adult mice after postnatal remodelling, and demonstrated that these βIrKO
mice were able to maintain euglycemic levels similar to control mice. This could be
because our βIrKO mice underwent normal pancreatic formation and remodelling with
the presence of β-cell IR, allowing proper β-cell maturation and prolonging β-cell
function. These results suggest that β-cell IR could be crucial for β-cell remodelling
during the first 21 days of postnatal life. The importance of fetal β-cell IR is further
supported by our prenatal βIrKO results, where the loss of fetal β-cell IR elicited an islet
growth response, indicating the importance of prenatal β-cell IR. Therefore, our postnatal
inducible βIrKO study demonstrates that the protein levels of β-cell IR and β-cell IR loss
at the examined age of interest could exert a key influence in β-cell function and β-cell
mass maintenance.
Surprisingly, both control and βIrKO mice manifested impaired glucose tolerance at 20
weeks post-tamoxifen when compared to younger mice. This could be attributed to the
genetic composition of the B6 mice. It has been reported that glucose tolerance tests
performed on B6 mice after 18 weeks on either low- or high-fat diet revealed impaired
glucose tolerance on both diets. Furthermore, the mixed genetic background of B6 and
129 manifested a larger degree of heterogeneity when it comes to dietary intake and
spontaneous obesity (Almind et al. 2004). This may explain the observed variability in
glucose tolerance tests at 20 weeks post-tamoxifen. Coinciding with these metabolic
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studies, islet morphological analyses at 20 weeks post-tamoxifen did not show any
differences in islet size or β-cell mass. Therefore, our statistically insignificant results are
likely due to the genetic background and variable levels of Ir knock out in mice.

4.5

Do postnatally induced β-cell-specific knockout mice exhibit

glucose intolerance after high-fat diet stress?45
Previously, it has been shown that when congenital βIrKO mice were fed a highfat diet for 20 weeks, a percentage of mice died prior to the end of the study while others
manifested obesity and hyperglycemia (Okada et al. 2007). Morphologically, these
βIrKO mice failed to develop the islet compensatory growth responses seen in control
mice, suggesting the necessity of β-cell IR for growth response (Okada et al. 2007). In
addition, Mehran et al. (2012) demonstrated that heterozygous insulin knockout B6 mice
do not develop islet compensatory growth, hyperinsulinemia, or obesity under high-fat
diet while control mice developed diabetic phenotypes, further suggesting that β-cell
insulin signalling is required for β-cell compensatory response to high-fat diet. In an
attempt to better understand the role of β-cell insulin signalling during metabolic stress,
we fed postnatally induced βIrKO mice a 6-week of high-fat diet starting at 2 weeks after
tamoxifen injection. We proposed to determine whether varying levels of β-cell IR could
potentially prevent diet-induced obesity similar to the findings from the heterozygous
insulin knockout mouse model (Mehran et al. 2012). Interestingly, all experimental
groups (control, heterozygous, and βIrKO), displayed similar levels of impaired glucose
tolerance compared to mice on chow-diet, but are equally sensitive to insulin after 6
weeks of high-fat diet. In addition, at the end of the high-fat diet period, the body weight
and fasting blood glucose of these groups did not significantly differ from mice on chowdiet. This could be because these mice were subjected to high-fat diet for only 6 weeks,
and β-cell compensatory proliferation may not be obvious until after 14 weeks on highfat diet (Roat et al. 2014). Therefore, we need to implement a longer term high-fat diet
study to determine the effect of postnatally induced βIrKO.
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4.6

Limitations46
The present study is performed on transgenic mouse models. Despite the

similarity in genetic composition and conservation of the insulin receptor gene between
humans and mice, significant differences exist. For instance, the organization of
pancreatic islets is different, and IR appears to play different roles during embryonic
development. Similar to mice, humans lacking IR expression during embryonic
development are viable at birth. However, mutations of IR in humans lead to postnatal
heterogeneous phenotypes ranging from mild insulin resistance to leprechaunism (Nakae
et al. 2001). These similarities and differences should be considered when translating
these studies to humans.
In addition, we utilized the MIP to drive Cre recombinase expression specifically limited
to pancreatic β-cells (Tamarina et al. 2014). However, one study has demonstrated
ectopic expression of MIP in neurons of the hypothalamus (Wang et al. 2014). Therefore,
we may face similar limitations to previous studies that used the RIP, which also has
ectopic expression in the hypothalamus. Ectopic activity of Cre recombinase, and the
subsequent knockdown of Ir, in the hypothalamus during embryonic development could
adversely affect energy homeostasis and metabolism in postnatal life (Wicksteed et al.
2010).
Another limitation is the incomplete knockout of β-cell IR protein levels in βIrKO mice.
As mentioned above, we only observed around ~75% and ~50% β-cell Ir knockdown in
fetal and adult βIrKO mice, respectively. Since remaining IR on β-cells are likely
functional, we only investigated the effect of a partial β-cell Ir knockdown, but cannot
determine the consequences of a complete β-cell Ir knockout. Furthermore, since we are
unable to isolate islets from fetal pancreata due to technical difficulties, all fetal western
blot data are representative of the whole pancreas, comprised of both the exocrine
compartment and endocrine islets.
Lastly, because we observed an islet growth response in the fetal βIrKO study, we have
attempted to generate neonatal mice in order to examine the consequences of diminishing
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IGF2 levels after birth on the neonatal (p21) islet morphology. However, tamoxifen
injected pregnant mothers have consistently killed newborn litters. Although it is not well
documented, it is possible that the tamoxifen injection adversely affects the health of the
pregnant mother or newborns and as a result, they are neglected by the mother. We are
currently working to obtain neonatal samples by fostering with pregnant CD-1 mice.

4.7

Conclusion and Future directions47

This thesis demonstrated that the β-cell IR plays an important role in fetal islet
development, while the varying levels of β-cell IR did not affect postnatal glucose
homeostasis. By understanding the temporal role of β-cell IR during different
developmental stages, we can potentially promote the survival and function of clinically
isolated islets by administering exogenous ligands, such as insulin and IGF2, to stimulate
downstream insulin receptor signalling pathways in β-cells. This may improve the longterm success of current cell-based therapies for diabetes by altering the β-cell IR activity
on donor islets prior to islet transplantation.
To further investigate the results from the fetal βIrKO study, we will continue to examine
islet morphology during the neonatal period, up until p21. We concluded that the
increased islet growth observed in fetal βIrKO mice is likely due to increased IGF2, but
IGF2 levels rapidly diminishes after birth in rodents (Hill et al. 1999). Therefore, we
should investigate the consequences of diminishing IGF2 on the pancreatic islet mass,
and better understand the consequential adaptation between different signalling networks.
For the postnatally induced βIrKO studies, we should subject these experimental groups
to high-fat diet for a longer period of time since we did not observe clear insulin
resistance after 6 weeks of high-fat diet. Currently, we have in vivo metabolic data and
islet morphology analyses at 24 weeks of age (20 weeks post-tamoxifen) for experimental
mice on chow diet. Corresponding to this age group, we propose to subject animals on
high-fat diet for 18 weeks starting at 6 weeks of age (2 weeks post-tamoxifen). We expect
to observe decreased peripheral insulin sensitivity and diabetic phenotypes at the end of
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the high-fat diet treatment, and will then examine the islet morphology and metabolic
differences between βIrKO, heterozygous, and control mice.
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Permit Holder

Wang, Rennian

Permit #

BIO-LHRI-0046

Department

Physiology

Phone

5196858500

Email

rwang@uwo.ca

Approval Date

Apr 25, 2014

Classification

2

Ext. 55098

Expiration Date

Apr 24, 2017

BioSafety Officer's Signature

Organism
Cell

Human (primary), fetal pancreas and duodenum, Rodent (primary), mouse pancreatic islets, human (established), PANC-1, HEK293,
Rodent (established), INS-1, AR42J

Human

organs and tissues (unpreserved), organs and tissues (preserved)

Gene Therapy
GMO
Animals

B6 mice

Toxin

Streptozotocin, Tamoxifen

Plant/Insect
Building
Other

Room
Room Area
OFF CAMPUS

April-28-14

Lab Phone
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Level
2
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Permit Summary
Permit Holder
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Permit #

BIO-LHRI-0046

Department

Physiology

Phone

5196858500

Email

rwang@uwo.ca

Approval Date

Apr 25, 2014

Classification

2

Ext. 55098

Expiration Date

Apr 24, 2017

BioSafety Officer's Signature

Permit Conditions
1

INTERNAL PERMIT HOLDER RESPONSIBILITIES
Comply with UWO BioSafety Safety Policies and Standard Operating Procedures. Ensure that the Health Canada Biosafety Guidelines, relevant
regulations and safe laboratory practices are followed.

1.1

Receive adequate biosafety training from the institution. Permit Holders are responsible for the provision of specific training and instruction in
biohazard agent handling that is necessary for the safe use of this material in their own laboratories. Supervisors must ensure that workers
understand the health and safety hazards of the work or task (due diligence).

1.2

Ensure that the UWO Biosafety Manual is available to all lab personnel under the permit.

1.3

Report incidents of loss or theft of any biohazardous material immediately to the Biosafety Coordinator;

2

WORKER RESPONSIBILITIES
Be familiar with the UWO Biosafety Manual, attend all required safety training sessions and obey all safety regulations required by the UWO
Biosafety Committee.

2.1

Report to the Permit Holder any incident involving known or suspected exposure, personal contamination or a spill involving a biohazardous agent.

I accept the above responsibilities as a Internal Permit Holder and I am accountable for following UWO BioSafety Guidelines and Procedures Manual for
Containment Level 1 and 2 Laboratories.
Permit Holder Name

Signed

Date

April-28-14
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Appendix C: Animal Use Protocol
Subject: eSirius Notiﬁcation - Annual Protocol Renewal
APPROVED by the AUS 2008-038-04::6
To:
Cc:

Date: 11/28/14 11:51 AM
From: esiriusadmin@uwo.ca, (eSiriusWebServer)

2008-038-04::6:
AUP Number: 2008-038-04
AUP Title: Pancreatic Beta Cell Development: The Role of the c-Kit and Integrin Receptors
Yearly Renewal Date: 11/01/2014
The YEARLY RENEWAL to Animal Use Protocol (AUP) 2008-038-04 has been approved,
and will be approved for one year following the above review date.
This AUP number must be indicated when ordering animals for this project.
Animals for other projects may not be ordered under this AUP number.
Purchases of animals other than through this system must be cleared through the ACVS ofﬁce.
Health certiﬁcates will be required.

REQUIREMENTS/COMMENTS
Please ensure that individual(s) performing procedures on live animals, as described in this
protocol, are familiar with the contents of this document.
The holder of this Animal Use Protocol is responsible to ensure that all associated safety
components (biosafety, radiation safety, general laboratory safety) comply with institutional
safety standards and have received all necessary approvals. Please consult directly with your
institutional safety officers.
Submitted by: Kinchlea, Will D
on behalf of the Animal Use Subcommittee
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